ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1638173
This article is part of the Research TopicNovel Therapeutic Approaches for Biliary Tract Cancer and Hepatocellular Carcinoma, Volume IIView all 6 articles
Hepatic Arterial Infusion Chemotherapy combined with Lenvatinib and Toripalimab for Large Hepatocellular Carcinoma(> 10 cm) with Major Portal Vein Tumor Thrombosis: A Multicenter Propensity Score Matching Analysis
Provisionally accepted- 1First Affiliated Hospital of Jinan University, Guangzhou, China
- 2Shenzhen Nanshan People's Hospital, Shenzhen, China
- 3Zhuhai City People's Hospital, Zhuhai, China
- 4Nanchang University Second Affiliated Hospital, Nanchang, China
- 5Jinan University, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
[Abstract] Background: Portal vein main trunk tumor thrombus is one of the most intractable complications of hepatocellular carcinoma(HCC), often occurring in patients with high intrahepatic tumor burden(>10 cm). High tumor burden HCC complicated by portal vein main trunk tumor thrombus is regarded as the very advanced stage with extremely poor therapeutic efficacy and very limited treatment options and its long-term survival depends on the dual remission of intra-hepatic tumors and tumor thrombi. Previous phase III trials have confirmed the ability of HAIC to effectively relieve high tumor burden HCC, yet HAIC alone cannot effectively manage tumor thrombi and intrahepatic progression. The efficacy of the combination of HAIC, lenvatinib and toripalimab in advanced HCC has also been confirmed by existing clinical evidence. Therefore, the combination of HAIC, lenvatinib and toripalimab may be a potentially effective treatment regimen for high tumor burden HCC complicated by portal vein main trunk tumor thrombus. Methods: A retrospective review was conducted on the clinical data of patients with high tumor burden HCC complicated by main portal vein tumor thrombus who received HAIC combined with lenvatinib and toripalimab(HAICLT group) or HAIC alone(HAIC group) from August 2019 to December 2023. Propensity score matching was employed to balance the baseline differences between the groups. The overall survival time, progression-free survival time, objective response rate, and disease control rate were compared between the groups. Results: After PSM, the median OS and median PFS of the HAICLT group were 21.2 months and 7.4 months respectively, significantly better than 6.6 months( P < 0.001) and 3.0 months(P < 0.001) of the HAIC group. In terms of treatment response, the HAICLT group also accomplished higher rates of intrahepatic responses and PVTT responses compared to the HAIC group. No significant statistical differences were found in the incidence rates of adverse events at all grades and grades 3 - 4 between the groups. Conclusion: Compared with HAIC alone, the combination of HAIC, lenvatinib, and toripalimab can effectively prolong the survival prognosis of patients with large HCC complicated by major PVTT and achieve intrahepatic and PVTT remission. It is a promising treatment approach.
Keywords: Hepatocellular Carcinoma, Hepatic artery infusion chemotherapy, Lenvatinib, Toripalimab, high tumor burden, Portal vein tumor thrombosis, Propensity score matching
Received: 11 Jun 2025; Accepted: 06 Oct 2025.
Copyright: © 2025 Yangyang, Wang, Zhang, Zheng, Song, Ran and Cai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yang Ran, ryang@jnu.edu.cn
Xiangran Cai, 15915793951@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.